Search

Your search keyword '"Nomura, Akihiro"' showing total 407 results
Start Over Author "Nomura, Akihiro" Language english
407 results on '"Nomura, Akihiro"'

1. Feasibility of a Novel Mobile C-Reactive Protein–Testing Device Using Gold-Linked Electrochemical Immunoassay: Clinical Performance Study

Author

Gondoh-Noda, Yuko, Kometani, Mitsuhiro, Nomura, Akihiro, Aono, Daisuke, Karashima, Shigehiro, Ushijima, Hiromi, Tamiya, Eiichi, Murayama, Toshinori, and Yoneda, Takashi

Subjects
Information technology, T58.5-58.64, Public aspects of medicine, RA1-1270
Abstract

BackgroundHome-based care is one of the most promising solutions to provide sufficient medical care for several older patients in Japan. However, because of insufficient diagnostic devices, it is sometimes difficult to detect early signs of the occurrence or worsening of diseases, such as infections under home-based care settings. C-reactive protein (CRP) is highly sensitive to diagnosing infections, and its elevation can help diagnose acute infection in older patients. Therefore, a CRP-measuring device that can be used in such a specific occasion is needed for home-based care. However, aspects such as its size, weight, and procedure are still challenging with respect to the practical use of mobile devices that quantitatively measure CRP levels easily and quickly under home-based care settings. ObjectiveWe developed a new mobile, rapid CRP measurement device using a gold-linked electrochemical immunoassay (GLEIA) system. The aim of this study was to evaluate the feasibility of this mobile CRP-testing device. MethodsFirst, we assessed the performance of bare GLEIA-based electrode chips as the foundation of the device. After embedding the bare GLEIA-based electrode chips in a special plastic case and developing the mobile CRP-testing device, we further tested the device prototype using clinical blood samples. Finally, we evaluated the intra-assay variability for precision in the same condition and inter-assay variability for reproducibility in different conditions. ResultsBlood samples for analysis were obtained by direct vein puncture from outpatients (N=85; females: 57/85; males: 28/85; age: 19-88 years) at Kanazawa University Hospital in Japan. For performance evaluation of bare GLEIA-based electrode chips, we used 85 clinical blood samples. There was a significant positive correlation between the electrode-predicted CRP levels and the reference CRP concentrations (R2=0.947; P

Published
2020
Full Text
View/download PDF

2. Efficacy of the Ascure Smoking Cessation Program: Retrospective Study

Author

Kato, Ayaka, Tanigawa, Tomoyuki, Satake, Kohta, and Nomura, Akihiro

Subjects
Information technology, T58.5-58.64, Public aspects of medicine, RA1-1270
Abstract

BackgroundSmoking cessation helps extend a healthy life span and reduces medical expenses. However, the standard 12-week smoking cessation program in Japan has several notable problems. First, only 30% of participants complete this program. Second, participants may choose not to participate unless they have a strong motivation to quit smoking, such as health problems. Third, the program does not provide enough support during the period between clinical visits and after 12 weeks. ObjectiveThis study examined the efficacy of the 24-week ascure program to address the problems of accessibility and continuous support. The program combines online mentoring, over-the-counter pharmacotherapy, and a smartphone app. MethodsUsing a retrospective study design, we investigated data for 177 adult smokers who were enrolled in the ascure smoking cessation program between August 2017 and August 2018. The primary outcomes were continuous abstinence rates (CARs) during weeks 9-12 and weeks 21-24. To confirm smoking status, we performed salivary cotinine testing at weeks 12 and 24. We also evaluated the program adherence rate. Finally, we performed exploratory analysis to determine the factors associated with continuous abstinence at weeks 21-24 to provide insights for assisting with long-term continuous abstinence. ResultsThe CARs of all participants for weeks 9-12 and weeks 21-24 were 48.6% (95% CI 41.2-56.0) and 47.5% (95% CI 40.0-54.8), respectively. Program adherence rates were relatively high throughout (72% at week 12 and 60% at week 24). In the analysis of the factors related to the CAR at weeks 21-24, the number of entries in the app’s digital diary and number of educational videos watched during the first 12 weeks were significant factors. ConclusionsThe ascure program achieved favorable CARs, and participants showed high adherence. Proactive usage of the smartphone app may help contribute to smoking cessation success in the long-term.

Published
2020
Full Text
View/download PDF

3. Adjuvant Alpha-Fetoprotein-Derived Peptide After Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma: Protocol for a Safety Study

Author

Nomura, Akihiro, Terashima, Takeshi, Mizukoshi, Eishiro, Kitahara, Masaaki, Murayama, Toshinori, and Kaneko, Shuichi

Subjects
Medicine, Computer applications to medicine. Medical informatics, R858-859.7
Abstract

BackgroundHepatocellular carcinoma (HCC) is a worldwide health concern because of a continued increase in cases globally; furthermore, the prognosis for patients with HCC remains poor. Transarterial chemoembolization (TACE) has been established as the standard of care for the intermediate stage of HCC; however, no therapeutic agents are available to reduce the high rate of recurrence. ObjectiveThis study aims to evaluate the safety of alpha-fetoprotein (AFP)-derived peptides for patients with HCC post-TACE. MethodsThis will be an open-label, single-arm, multicenter study to evaluate the safety of AFP-derived peptides (AFP 357 and AFP 403), which contain histocompatibility antigen-A24-restricted cytotoxic T lymphocyte epitopes from tumor antigens expressed in HCC and is recognized at a high rate by lymphocytes in patients with HCC. Protocol treatment will consist of six courses of the subcutaneous administration of 3 mg each of AFP 357 and AFP 403. A total of 14 patients will be included in this study, the first 6 as a main analysis target group and an additional 8 as an extended cohort from three institutions in Japan. The primary endpoint will be the occurrence of serious adverse events (safety profile). The secondary endpoints will include time to progression, overall survival, completion rate, and adverse events (efficacy profile). ResultsWe have recruited 14 patients with HCC as of December 2019. The final follow-up will be completed by March 2020. ConclusionsIn this study, we will evaluate the safety profile of AFP-derived peptides for patients with HCC post-TACE. We believe that this study will provide useful information and will help to design a subsequent phase II trial based on the results. Trial RegistrationJapan Registry of Clinical Trials jRCTs041180155; https://jrct.niph.go.jp/latest-detail/jRCTs041180155 International Registered Report Identifier (IRRID)DERR1-10.2196/17082

Published
2020
Full Text
View/download PDF

4. Impact of a Novel Smartphone App (CureApp Smoking Cessation) on Nicotine Dependence: Prospective Single-Arm Interventional Pilot Study

Author

Masaki, Katsunori, Tateno, Hiroki, Kameyama, Naofumi, Morino, Eriko, Watanabe, Riri, Sekine, Kazuma, Ono, Tomohiro, Satake, Kohta, Suzuki, Shin, Nomura, Akihiro, Betsuyaku, Tomoko, and Fukunaga, Koichi

Subjects
Information technology, T58.5-58.64, Public aspects of medicine, RA1-1270
Abstract

BackgroundMobile apps have been considered to provide active and continuous support for smoking cessation. However, it is yet to be known whether a smoking cessation smartphone app improves long-term abstinence rates in nicotine-dependent patients. ObjectiveThis study aimed to evaluate the long-term abstinence effect of a novel smartphone app, CureApp Smoking Cessation (CASC), in patients with nicotine dependence. MethodsIn this prospective, interventional, multicenter, single-arm study, we provided the CASC app to all the participants, who used it daily for 24 weeks. The CASC app includes features to maximize the therapeutic effect of pharmacological therapies and counseling at outpatient clinics for smoking cessation. The primary endpoint was a continuous abstinence rate (CAR) from weeks 9 to 24, whereas secondary endpoints were CARs from weeks 9 to 12 and 9 to 52. ResultsOf the 56 adult smokers recruited, 1 did not download the app; therefore, 55 participants constituted the full analysis sample. The CAR from weeks 9 to 24 was 64% (35/55, 95% CI 51%-76%), whereas the CARs from weeks 9 to 12 and 9 to 52 were 76% (42/55, 95% CI 65%-88%) and 58% (32/55, 95% CI 46%-71%), respectively. These CARs were better than the results of the national survey on outpatient clinics with regard to smoking cessation under the National Health Insurance Program and that of the varenicline phase 3 trial in Japan and the United States. There was only 1 participant who dropped out during the 12 weeks of the treatment period. This treatment decreased the scores related to withdrawal and craving symptoms. ConclusionsThe addition of CASC to usual smoking cessation therapies resulted in high CARs, high patient retention rates, and improvement of cessation-related symptoms. The smartphone app CASC is a feasible and useful tool to help long-term continuous abstinence that can be combined with a standard smoking cessation treatment program.

Published
2019
Full Text
View/download PDF

8. Human leukocyte antigen-DQ risk heterodimeric haplotypes of left ventricular dysfunction in cardiac sarcoidosis: an autoimmune view of its role

Author

Yamamoto, Hironori, Miyashita, Yohei, Minamiguchi, Hitoshi, Hosomichi, Kazuyoshi, Yoshida, Shohei, Kioka, Hidetaka, Shinomiya, Haruki, Nagata, Haruno, Onoue, Kenji, Kawasaki, Masato, Kuramoto, Yuki, Nomura, Akihiro, Toma, Yuichiro, Watanabe, Tetsuya, Yamada, Takahisa, Ishihara, Yasuki, Nagata, Miho, Kato, Hisakazu, Hakui, Hideyuki, Saito, Yoshihiko, Asano, Yoshihiro, and Sakata, Yasushi

Published
2023
Full Text
View/download PDF

9. Efficacy of azilsartan on left ventricular diastolic dysfunction compared with candesartan: J-TASTE randomized controlled trial

Author

Ito, Shin, Takahama, Hiroyuki, Asakura, Masanori, Abe, Yukio, Ajioka, Masayoshi, Anzai, Toshihisa, Arikawa, Takuo, Hayashi, Takaharu, Higashino, Yorihiko, Hiramitsu, Shinya, Iwahashi, Noriaki, Izumi, Chisato, Kimura, Kazuo, Kinugawa, Koichiro, Kioka, Hidetaka, Lim, Young-Jae, Matsuoka, Ken, Matsuoka, Satoshi, Motoki, Hirohiko, Nakamura, Sunao, Nakayama, Takafumi, Nomura, Akihiro, Sasaoka, Taishi, Takiuchi, Shin, Toyoda, Shigeru, Ueda, Tomoya, Watanabe, Tetsuya, Yamada, Akira, Yamamoto, Masayoshi, Sozu, Takashi, and Kitakaze, Masafumi

Published
2023
Full Text
View/download PDF

13. Characterization of baseline clinical factors associated with incident worsening kidney function in patients with non-valvular atrial fibrillation: the Hokuriku-Plus AF Registry

Author

Hayashi, Kenshi, Tanaka, Yoshihiro, Tsuda, Toyonobu, Nomura, Akihiro, Fujino, Noboru, Furusho, Hiroshi, Sakai, Norihiko, Iwata, Yasunori, Usui, Soichiro, Sakata, Kenji, Kato, Takeshi, Tada, Hayato, Kusayama, Takashi, Usuda, Keisuke, Kawashiri, Masa-aki, Passman, Rod S., Wada, Takashi, Yamagishi, Masakazu, and Takamura, Masayuki

Published
2023
Full Text
View/download PDF

19. The utility of zebrafish cardiac arrhythmia model to predict the pathogenicity of KCNQ1 variants

Author

Cui, Shihe, Hayashi, Kenshi, Kobayashi, Isao, Hosomichi, Kazuyoshi, Nomura, Akihiro, Teramoto, Ryota, Usuda, Keisuke, Okada, Hirofumi, Deng, Yaowen, Kobayashi-Sun, Jingjing, Nishikawa, Tetsuo, Furusho, Hiroshi, Saito, Takekatsu, Hirase, Hiroaki, Ohta, Kunio, Fujimoto, Manabu, Horita, Yuki, Kusayama, Takashi, Tsuda, Toyonobu, Tada, Hayato, Kato, Takeshi, Usui, Soichiro, Sakata, Kenji, Fujino, Noboru, Tajima, Atsushi, Yamagishi, Masakazu, and Takamura, Masayuki

Published
2023
Full Text
View/download PDF

27. Correction: Characterization of baseline clinical factors associated with incident worsening kidney function in patients with non-valvular atrial fibrillation: the Hokuriku-Plus AF Registry

Author

Hayashi, Kenshi, Tanaka, Yoshihiro, Tsuda, Toyonobu, Nomura, Akihiro, Fujino, Noboru, Furusho, Hiroshi, Sakai, Norihiko, Iwata, Yasunori, Usui, Soichiro, Sakata, Kenji, Kato, Takeshi, Tada, Hayato, Kusayama, Takashi, Usuda, Keisuke, Kawashiri, Masa-aki, Passman, Rod S., Wada, Takashi, Yamagishi, Masakazu, and Takamura, Masayuki

Published
2023
Full Text
View/download PDF

47. Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol

Author

Takeuchi, Akihiko, Nomura, Akihiro, Yamamoto, Norio, Hayashi, Katsuhiro, Igarashi, Kentaro, Tandai, Susumu, Kawai, Akira, Matsumine, Akihiko, Miwa, Shinji, Nishida, Yoshihiro, Nakamura, Tomoki, Terauchi, Ryu, Hoshi, Manabu, Kunisada, Toshiyuki, Endo, Makoto, Yoshimura, Kenichi, Murayama, Toshinori, and Tsuchiya, Hiroyuki

Published
2019
Full Text
View/download PDF

50. Impact of clinical and echocardiographic characteristics on occurrence of cardiac events in cardiac amyloidosis as proven by endomyocardial biopsy

Author

Nakahashi, Takuya, Arita, Takeshi, Yamaji, Kyohei, Inoue, Katsumi, Yokota, Tadaaki, Hoshii, Yoshinobu, Fukunaga, Masato, Nomura, Akihiro, Watanabe, Hirotoshi, Miura, Shirou, Isotani, Akihiro, Soga, Yoshimitsu, Ando, Kenji, Iwabuchi, Masashi, Yokoi, Hiroyoshi, Nosaka, Hideyuki, Yamagishi, Masakazu, and Nobuyoshi, Masakiyo

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results